Novel Immune Cell Culture Technology Through Glycan Modification and Metabolic Control
First written in FY2019. 4 of 8 entries say "Advanced", first in FY2020-Q2. Latest entry: FY2023.
No other company in this theme has enough history to compare yet.
- FY2023AdvancedAnnual report
「The Company conducted with Medical Corporation Shadan 滉志会 (the "滉志会") a clinical study to assess in humans the safety and efficacy of lymphocytes (2-DG lymphocytes) produced using its novel immune cell culture technology based on glycan modification and metabolic control, and confirmed that there were no safety concerns.」
For 2-DG lymphocytes, the Company confirmed the absence of safety concerns in its clinical study with 滉志会 and proceeded to investigate their application to CAR-T cells and obtain a patent grant in Japan. - FY2023-Q2SoftenedAnnual report
「We will extend the planned expenditure period because additional quality and nonclinical testing is required.」
Additional quality and nonclinical testing became necessary for the development of glycan-modified T cells and other products, extending the scheduled expenditure period for the stated use of funds through March 2026. - FY2022-Q3RestatedAnnual report
「The Company established a collaborative research chair in immune regeneration control at the Graduate School of Medicine, Osaka University, and has conducted research on immune cells. It is conducting, jointly with Medical Corporation Shadan 滉志会, a clinical study to assess in humans the safety and efficacy of lymphocytes (2-DG lymphocytes) produced using the resulting novel immune cell culture technology based on glycan modification and metabolic control.」
The Company has continued its joint clinical study with 滉志会 to assess the safety and efficacy of 2-DG lymphocytes in humans. - FY2022-Q2RestatedAnnual report
「The Company is conducting, jointly with Medical Corporation Shadan 滉志会, a clinical study to assess in humans the safety and efficacy of lymphocytes (2-DG lymphocytes) produced using its novel immune cell culture technology based on glycan modification and metabolic control.」
The Company has continued its joint clinical study with 滉志会 to assess the safety and efficacy of 2-DG lymphocytes in humans. - FY2022-Q1AdvancedAnnual report
「The Company jointly commenced with Medical Corporation Shadan 滉志会 a clinical study to assess in humans the safety and efficacy of lymphocytes (2-DG lymphocytes), a result of its research into novel immune cell culture technology using glycan modification and metabolic control. The Company is also investigating the potential application of the immune cells cultured using this technology to CAR-T cells, as they have desirable characteristics as immune cells.」
For 2-DG lymphocytes produced using glycan modification and metabolic control, the Company began a clinical study with 滉志会 to assess safety and efficacy in humans and proceeded to investigate their potential application to CAR-T cells. - FY2020-Q3AdvancedAnnual report
「Costs related to the development of novel regenerative medicine products, including glycan-modified T cells, for intractable gastrointestinal cancers」
The stated use of proceeds from the 16th Stock Acquisition Rights included development costs for novel regenerative medicine products using glycan-modified T cells and other products. - FY2020-Q2AdvancedAnnual report
「Development costs for regenerative medicine products, including glycan-modified T cells: ¥812 million, July 2019 to September 2021」
The stated use of funds was ¥812 million for the development of glycan-modified T cells and other products, to be spent from July 2019 through September 2021. - FY2019First statedAnnual report
「As a result of our research, we discovered novel immune cell culture technology using glycan modification and metabolic control. The immune cells cultured using this technology have desirable characteristics as immune cells and may become a platform technology for next-generation immunotherapy. We are currently evaluating this potential.」
The Company discovered novel culture technology through research with Osaka University and is evaluating its potential as a platform technology for next-generation immunotherapy.